BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms Clinical Trial

Official title:

Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01145885
• Other study ID #: 1230.23
• Secondary ID: 2009-018199-32
• Status: Completed
• Phase: Phase 1
• Start date: June 2010
• Est. completion date: November 2010

Study information

• Verified date: August 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigation of absorption, distribution, metabolism and excretion (ADME) and assessment of safety, tolerability and preliminary therapeutic effects of [14C]volasertib in patients with advanced solid tumours.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria:

• Inclusion Criteria 1. Patients with histologically or cytologically confirmed diagnosis of advanced, non resectable and / or metastatic solid tumour

• Inclusion Criteria 2. Male

• Inclusion Criteria 3. Age >=18 and =<70 years

• Inclusion Criteria 4. Written informed consent

• Inclusion Criteria 5. Eastern Cooperative Oncology Group (ECOG) performance score =<2

• Inclusion Criteria 6. Recovery from Common Terminology Criteria for Adverse Events (CTCAE) Grade >=2 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapy

Exclusion criteria:

• Exclusion Criteria 1. Serious concomitant non-oncological disease considered by the investigator

• Exclusion Criteria 2. Active infectious disease

• Exclusion Criteria 3. Viral hepatitis, Human Immunodeficiency Virus (HIV) infection

• Exclusion Criteria 4. Clinical evidence of active brain metastasis during the past 6 months

• Exclusion Criteria 5. Second malignancy currently requiring active therapy

• Exclusion Criteria 6. Absolute neutrophil count less than 1,500/mm3

• Exclusion Criteria 7. Platelet count less than 100,000/mm3

• Exclusion Criteria 8. Total bilirubin greater than 1.5 mg/dL

• Exclusion Criteria 9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)

• Exclusion Criteria 10. Serum creatinine greater than 1.5x Upper Limit of Normal (ULN).

• Exclusion Criteria 11. Known history of QT/QTcF-prolongation

• Exclusion Criteria 12. Patients who are sexually active and having a partner with childbearing potential and unwilling to use a medically acceptable method of contraception

• Exclusion Criteria 13. Treatment with other investigational drugs or participation in another clinical trial

• Exclusion Criteria 14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy within the past four weeks prior to start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.

• Exclusion Criteria 15. Alcohol abuse

• Exclusion Criteria 16. Life expectancy less than 12 weeks

• Exclusion Criteria 17. Potent Cytochrome P450 enzyme (CYP) 3A4 and P-glycoprotein inhibitors or inducers

• Exclusion Criteria 18. History of allergy/hypersensitivity

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BI 6727
PLK-1 inhibitor

Locations

Country	Name	City	State
Hungary	1230.23.36001 Boehringer Ingelheim Investigational Site	Budapest

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Individual Time Course Profiles of 14C-radioactivity in Whole Blood and Plasma: Cmax of 14C Labelled Volasertib	Individual time course profiles of 14C-radioactivity in whole blood and plasma: Cmax of 14C labelled Volasertib.	Whole blood: Pre-dose (-0.5 hours (h)) and 1.0h, 1.983h, 4h, 6h, 8h and 24h after start of the 2h drug infusion.Plasma: Pre-dose (-0.5h) and 1.0h, 1.983h, 4h, 6h, 8h, 24h,48h. 96h, 168h and 336h after start of drug infusion.
Primary	Individual Time Course Profiles of 14C-radioactivity in Urine: Cumulative Fraction of 14C-ratioactivity Excreted in Urine	Percentage of administered dose excreted in urine as 14C-radioactivity over time	Every 24 hours, up to 504 hours
Primary	Individual Time Course Profiles of 14C-radioactivity in Faeces: Cumulative Fraction of 14C-radioactivity Excreted in Faeces	Percentage of administered dose excreted in faeces as 14C-radioactivity over time	Every 24 hours, up to 504 hours
Primary	Individual Time Course Profiles of Volasertib and CD 10899 in Plasma: Cmax of Volasertib and CD 10899 (a Metabolite of Volasertib).	Individual time course profiles of volasertib (BI 6727) and a metabolite of volasertib (CD 10899), in plasma: Cmax of Volasertib and CD 10899.	Plasma: Pre-dose (-0.5h) and 1.0h, 1.983h, 4h, 6h, 8h, 24h,48h. 96h, 168h and 336h after start of drug infusion.
Primary	Individual Time Course Profile of Volasertib in Urine:Cumulative Fraction of Volasertib Excreted in Urine	Percentage of administered dose excreted in urine as volasertib (BI 6727) over time	Every 24 hours, up to 504 hours
Primary	Individual Time Course Profile of CD 10899 in Urine: Cumulative Amount of CD 10899 Excreted in Urine	Cumulative amounts of CD 10899, a metabolite of volasertib, excreted in urine over time	Every 24 hours, up to 504 hours
Primary	Rate and Extent of Excretion Mass Balance Based on the Total Radioactivity in Urine and Faeces: Cumulative Fraction of Excretion 504 Hours After Start of Drug Infusion.	Cumulative Percentage of 14C-radioactivity excreted in urine and faeces at 504 hours after start of drug infusion related to total [14C] volasertib administered.	up to 504 hours
Primary	Cmax of Volasertib and CD 10899 in Plasma	Maximum measured concentration of volasertib and CD 10899, a metabolite of volasertib, in plasma (Cmax).	30 minutes (min) before start of infusion and 1 hour (h), 1h 59min, 4h, 6h, 8h, 24h, 48h, 96h, 168h and 336h after start of infusion
Primary	AUC0-inf of Volasertib and CD10899 in Plasma	Area under the concentration-time curve of volasertib and CD 10899, a metabolite of volasertib, in plasma over the time interval from 0 to infinity (AUC0-inf).	30 minutes (min) before start of infusion and 1 hour (h), 1h 59min, 4h, 6h, 8h, 24h, 48h, 96h, 168h and 336h after start of infusion
Primary	CL/R of Volasertib and CD 10899 in Urine	Renal clearance of the analyte in urine (CL/R) within the time interval 0 hours to 504 hours of volasertib and CD 10899, a metabolite of volasertib.	Every 24 hours, up to 504 hours
Primary	Ae(0-tz) of Volasertib and CD 10899 in Urine	Amount of analyte eliminated in urine within the time interval 0 hours to last quantifiable data point (Ae(0-tz)) for volasertib and CD 10899, a metabolite of volasertib.	Every 24 hours, up to 504 hours
Primary	AUC0-tz of 14C Radioactivity in Plasma and Whole Blood	Area under the concentration-time curve of 14C radioactivity in plasma and whole blood over the time interval from 0 to the last quantifiable data point (AUC0-tz).	30 minutes (min) before start of infusion and 1 hour (h), 1h 59min, 4h, 6h, 8h, 24h, 48h, 96h, 168h and 336h after start of infusion for plasma; 30 min before start of infusion and 1h, 1h 59min, 4h, 6h, 8h and 24h after start of infusion for whole blood
Primary	Ae(0-tz) of 14C Radioactivity in Urine	Amount of analyte eliminated in urine within the time interval 0 to to the last quantifiable data point (Ae(0-tz)) of 14C radioactivity	Every 24 hours, up to 504 hours
Primary	Ae,Faeces(0-tz) of 14C Radioactivity	Amount of analyte excreted in faeces within the time interval 0 to to the last quantifiable data point (Ae(0-tz)) of 14C radioactivity	Every 24 hours, up to 504 hours
Primary	Time Dependency of Cblood Cells/Cplasma Ratio and Cblood/Cplasma Ratio of 14C-radioactivity	Time dependency of Cblood cells/Cplasma ratio and Cblood/Cplasma ratio of 14C-radioactivity.	1.983 hours and 6 hours
Primary	Elucidation of Metabolite Structures and Identification of Major Metabolites in Plasma, Urine, and Faeces	Elucidation of mb structures and identification of major metabolites in plasma, urine, and faeces. This endpoint was not analysed in the study report.; The contribution of volasertib and the metabolite CD 10899 to total radioactivity in plasma in the time interval 0 to 8 h after drug administration supports the suggestion that other metabolites in addition to CD 10899 are present in plasma. However, different methods used for the quantification of volasertib and CD 10899 (HPLC MS/MS) and total 14C-radioactivity (liquid scintillation counting) have to be taken into account for the interpretation of the difference between total 14C-radioactivity and analysis of volasertib and CD 10899 in plasma and the plasma metabolite pattern remains to be categorized.	3 weeks
Secondary	Percentage of Participants With Drug Related Adverse Events	Percentage of participants with drug related adverse events (AEs)	From first intake of study drug until 21 days after last intake of the study drug, up to 63 days
Secondary	Percentage of Participants With Clinically Relevant Abnormalities for Clinical Assessments, ECG, Vital Signs and Laboratory Tests	Percentage of participants with clinically relevant abnormalities for clinical assessments, electrocardiogram (ECG), vital signs and clinical laboratory test parameters. New abnormal findings or worsening of baseline conditions were reported as adverse events.	From first intake of study drug until 21 days after last intake of the study drug, up to 63 days
Secondary	Percentage of Participants With Clinical Benefit	The endpoint tumour response was was analysed as the percentage of participants with clinical benefit after each treatment cycle based on the Investigator's response assessment (with clinical assessment being conducted after every cycle and radiological assessment at the Investigator's discretion).	21, 42 and 63 days

External Links

•   Link